The June issue of Sterne Kessler’s MarkIt to Market™ newsletter contains information concerning the FDA’s draft guidance detailing the best practices for developing trademarks for drugs, the proposed fee reductions at the USPTO, and an updated list of the Sunrise periods currently open for new gTLDs.

In this issue:

Sterne Kessler’s Trademark, Advertising, and Anti-Counterfeiting practice is designed to help meet the intellectual property needs of companies interested in developing and maintaining strong brands around the world. For more information please contact Monica Riva Talley, Tracy-Gene G. Durkin, or Julie D. Shirk.